These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34653442)

  • 1. Multitarget 2'-hydroxychalcones as potential drugs for the treatment of neurodegenerative disorders and their comorbidities.
    Kamecki F; Knez D; Carvalho D; Marcucci C; Rademacher M; Higgs J; Žakelj S; Marcos A; de Tezanos Pinto F; Abin-Carriquiry JA; Gobec S; Colettis N; Marder M
    Neuropharmacology; 2021 Dec; 201():108837. PubMed ID: 34653442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo Biological Evaluation of Newly Tacrine-Selegiline Hybrids as Multi-Target Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer's Disease.
    Huang ST; Luo JC; Zhong GH; Teng LP; Yang CY; Tang CL; Jing L; Zhou ZB; Liu J; Jiang N
    Drug Des Devel Ther; 2024; 18():133-159. PubMed ID: 38283137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.
    Mathew B; Parambi DGT; Mathew GE; Uddin MS; Inasu ST; Kim H; Marathakam A; Unnikrishnan MK; Carradori S
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900177. PubMed ID: 31478569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
    Sang Z; Wang K; Shi J; Liu W; Tan Z
    Eur J Med Chem; 2019 Sep; 178():726-739. PubMed ID: 31229875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.
    Reeta ; Baek SC; Lee JP; Rangarajan TM; Ayushee ; Singh RP; Singh M; Mangiatordi GF; Nicolotti O; Kim H; Mathew B
    CNS Neurol Disord Drug Targets; 2019; 18(8):643-654. PubMed ID: 31550216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders.
    Mathew B; Oh JM; Baty RS; Batiha GE; Parambi DGT; Gambacorta N; Nicolotti O; Kim H
    Environ Sci Pollut Res Int; 2021 Aug; 28(29):38855-38866. PubMed ID: 33743158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and Selective Monoamine Oxidase-B Inhibitory Activity: Fluoro- vs. Trifluoromethyl-4-hydroxylated Chalcone Derivatives.
    Mathew B; Mathew GE; Uçar G; Baysal I; Suresh J; Mathew S; Haridas A; Jayaprakash V
    Chem Biodivers; 2016 Aug; 13(8):1046-52. PubMed ID: 27402375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective inhibition of human monoamine oxidase-B by 4-dimethylaminochalcone and selected chalcone derivatives.
    Oh JM; Kang MG; Hong A; Park JE; Kim SH; Lee JP; Baek SC; Park D; Nam SJ; Cho ML; Kim H
    Int J Biol Macromol; 2019 Sep; 137():426-432. PubMed ID: 31271801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones.
    Singh AK; Kim SM; Oh JM; Abdelgawad MA; Ghoneim MM; Rangarajan TM; Kumar S; Sudevan ST; Trisciuzzi D; Nicolotti O; Kim H; Mathew B
    Chem Biol Drug Des; 2023 Aug; 102(2):271-284. PubMed ID: 37011915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and Characterization of Neuroprotective Properties of Thaumatin-like Protein 1a from
    D'Errico A; Nasso R; Di Maro A; Landi N; Chambery A; Russo R; D'Angelo S; Masullo M; Arcone R
    Nutrients; 2024 Jan; 16(2):. PubMed ID: 38276545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
    Hitge R; Smit S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Joubert J; Foka GB; Repsold BP; Oliver DW; Kapp E; Malan SF
    Eur J Med Chem; 2017 Jan; 125():853-864. PubMed ID: 27744252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer's disease.
    Zhang X; Song Q; Cao Z; Li Y; Tian C; Yang Z; Zhang H; Deng Y
    Bioorg Chem; 2019 Jun; 87():395-408. PubMed ID: 30921741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer's disease therapy.
    Youdim MBH
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):715-721. PubMed ID: 35190910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoamine oxidase inhibitory activities of heterocyclic chalcones.
    Minders C; Petzer JP; Petzer A; Lourens AC
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5270-6. PubMed ID: 26432037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel AP2238-clorgiline hybrids as multi-target agents for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.
    Zhong G; Guo J; Pang C; Su D; Tang C; Jing L; Zhang F; He P; Yan Y; Chen Z; Liu J; Jiang N
    Bioorg Chem; 2023 Jan; 130():106224. PubMed ID: 36332315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
    Bai P; Wang K; Zhang P; Shi J; Cheng X; Zhang Q; Zheng C; Cheng Y; Yang J; Lu X; Sang Z
    Eur J Med Chem; 2019 Dec; 183():111737. PubMed ID: 31581002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
    Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
    Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
    Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.